17013-Melanoma-NA-1252

Melanoma

A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAFV600 WILD-TYPE MELANOMA (CO39722)

  • Details

ClinicalTrials.gov ID: NCT03273153
Diagnosis Type: NA
USOR Number: 17013

  • Address

7200 W Bell Road, Building A
Glendale, AZ 85308
P: (623) 487-4822

Find a Clinical Trial

Use the abbreviation for your state (ie. FL, TX, NV)
Search by practice name, trial titles, indicators and specific disease types.